Congenital Cytomegalovirus: Newborn Dosing And Hearing Follow-Up

Congenital cytomegalovirus (cCMV) is one of the most important infectious causes of childhood sensorineural hearing loss. A baby may appear well at birth and still develop delayed or progressive hearing impairment, so early testing and organised follow-up matter. The clinical picture ranges from an asymptomatic infant with an isolated failed hearing screen to severe disease involving the brain, liver, blood, eyes and growth.

Management requires more than selecting an antiviral dose. Clinicians need to confirm that CMV infection was acquired before birth, assess disease severity, calculate medication from the baby’s current weight and renal function, and arrange repeated audiology reviews. These decisions are especially relevant in Australia, where families may move between maternity hospitals, community services, rural centres and tertiary paediatric units.

Confirming Congenital CMV Early

A positive CMV polymerase chain reaction (PCR) from saliva or urine collected in the first 21 days of life supports congenital infection. Saliva is convenient for screening, but breast milk contamination can produce a false-positive result, so a positive saliva result should generally be confirmed with urine PCR. Testing after three weeks cannot reliably separate congenital infection from CMV acquired after birth.

A newborn who fails the hearing screen should receive prompt diagnostic assessment rather than waiting for a routine later appointment. The assessment may include auditory brainstem response (ABR), otoacoustic emissions and middle-ear evaluation, depending on age and clinical circumstances. CMV testing should occur quickly because the 21-day window is clinically important.

The original FAOPS 2020 meeting brought together perinatal and neonatal specialists around research and clinical practice, and its perinatal congress archive remains a useful reminder of the value of cross-disciplinary discussion. cCMV care benefits from the same approach: obstetric, neonatal, infectious diseases, audiology, pharmacy and early-intervention teams need to share information.

Deciding Who May Benefit From Treatment

Antiviral therapy is most strongly considered for infants with moderate-to-severe symptomatic cCMV, particularly when there is central nervous system involvement. Relevant findings can include microcephaly, abnormal neuroimaging, seizures, intracranial calcifications, ventriculomegaly, abnormal cerebrospinal fluid results, chorioretinitis or significant neurological signs. Thrombocytopenia, jaundice, hepatosplenomegaly, petechiae and poor growth may also indicate systemic disease.

The usual oral medicine is valganciclovir, the prodrug of ganciclovir. A commonly used neonatal regimen is 16 mg/kg per dose by mouth every 12 hours, usually continued for six months when treatment is indicated. This is a reference regimen, not a prescription: local protocols, gestational age, postnatal age, renal function, formulation and specialist advice must guide the final order.

An otherwise well infant with normal examination and imaging does not routinely receive antiviral treatment. Isolated sensorineural hearing loss is a more complex category. Some specialists may discuss treatment, particularly when diagnosed very early, but evidence for benefit in isolated hearing loss is less certain than it is for symptomatic disease involving the central nervous system.

Calculating The Newborn Dose Safely

Valganciclovir dosing is weight based, so the dose must be recalculated as the baby grows. A dose calculated at discharge can become inaccurate within days in a rapidly growing newborn. The prescriber should document the baby’s weight, dose in milligrams, volume in millilitres, concentration of the compounded or commercial liquid, frequency and the date for review.

Renal function is important because ganciclovir and valganciclovir are cleared through the kidneys. Prematurity, dehydration, acute kidney injury and changing creatinine levels may require specialist adjustment. Oral suspension should be prepared, stored and measured according to the product information and hospital pharmacy instructions. Families should use an oral syringe rather than a household spoon.

Caregivers need clear handling advice because the medicine can be hazardous. They should wash their hands after giving it, avoid contact with powder or spilled liquid, and follow pharmacy instructions for cleaning equipment and disposing of waste. A written medication plan is particularly valuable when a baby moves from a neonatal unit to a local hospital or general practitioner.

Monitoring Benefits And Toxicity

The principal adverse effects of valganciclovir are neutropenia, anaemia, thrombocytopenia and possible liver or renal toxicity. Monitoring commonly includes a full blood count, differential count, liver function tests and renal function. The schedule varies between services, but testing is often frequent during the first weeks and then spaced out when results are stable.

A low neutrophil count or other concerning result should trigger prompt contact with the treating team. Families should seek urgent advice for fever, unusual lethargy, poor feeding, pallor, bruising, bleeding or a marked reduction in wet nappies. They should not stop treatment or restart it independently after a missed dose or abnormal blood test.

The benefit of therapy is measured over time rather than by a single early hearing result. Treatment may reduce the risk of worsening hearing in selected symptomatic infants, but it cannot restore hearing already lost and does not remove the need for audiology. Drug toxicity, adherence, feeding tolerance and laboratory trends all form part of the review.

Building A Reliable Hearing Pathway

A baby with cCMV should have a diagnostic audiology assessment even if the initial screen was passed. Hearing loss may be present at birth, appear during infancy or progress later. ABR is particularly important for infants who cannot provide reliable behavioural responses. The timing should reflect the baby’s medical condition, but services aim for diagnosis by three months and early intervention by six months where hearing loss is confirmed.

Follow-up intervals are individualised. More frequent testing is appropriate for an infant with abnormal results, neurological disease or changing responses. As the child matures, behavioural audiometry can complement or replace electrophysiological testing. Audiologists should record each ear separately and explain whether a result reflects conductive factors, sensorineural loss or an uncertain response.

Families may need access to hearing aids, cochlear implant assessment, speech and language support, Auslan or other communication options, and developmental surveillance. Early intervention should begin on the basis of confirmed hearing needs rather than waiting for a child to “catch up”. Vision, motor development, feeding and neurological progress also deserve attention in symptomatic cCMV.

Making Follow-Up Work In Australia

Australia’s geography and health system can make continuity difficult. A family in regional Queensland, Western Australia or the Northern Territory may travel a long way for paediatric audiology, while a baby born in a metropolitan hospital may later be followed by a local service. The discharge summary should include the positive test, specimen date, imaging, treatment plan, dose, laboratory schedule and named referral contacts.

Public and private pathways may overlap, with care involving state newborn hearing programs, Medicare-funded appointments, Aboriginal Community Controlled Health Services, general practice and tertiary children’s hospitals. Families should be given a practical schedule rather than a general instruction to “follow up”. Telehealth can support medication reviews and case conferences, although it cannot replace every hearing assessment.

CMV exposure after birth is a separate issue from congenital infection. Breast milk contains CMV, which is usually not a concern for healthy term infants but may require a tailored discussion for very premature or very low-birth-weight babies. Broader changes in feeding practices during the pandemic are discussed in breastfeeding research coverage, although that context should not be used to replace individual neonatal advice.

Practical Checks For Families And Clinicians

A shared plan helps prevent missed appointments, dose errors and gaps between hospitals. Useful checks include:

• Confirm CMV by urine PCR when a saliva screen is positive.
• Record the current weight and recalculate the dose at every medication review.
• Arrange blood count, liver and renal monitoring through the treating service.
• Book diagnostic audiology and keep every scheduled hearing review.

Families can support safe follow-up by:

• Using the supplied oral syringe and checking the liquid concentration.
• Keeping a written record of doses, vomiting, missed doses and symptoms.
• Taking the discharge summary to the GP, child health nurse and audiology appointment.
• Contacting the clinical team promptly for fever, poor feeding, bruising or unusual sleepiness.

A coordinated plan gives babies with congenital CMV the best opportunity for timely antiviral assessment, early hearing support and developmental care. In Australia, families can ask their neonatal or paediatric team to identify the responsible specialist, confirm the next blood test and provide a written audiology schedule before leaving hospital.